News

Neurocrine Biosciences, a product based biopharmaceutical company, has announced top-line efficacy and safety results from its fourth Phase II clinical trial using its orally-active nonpeptide gonadotropin-releasing hormone receptor

Financial highlights Adjusted EBITDA(2) 2008: GBP12.3 million (Pro forma(1) 2007: GBP8 million) – 54% increase Operating Profit of GBP4.2 million (2007: GBP2 million) – 114% increase Adjusted basic

ReGen Therapeutics, a company engaged in the drug development and ancillary services, has signed an agreement with Golgi Pharmaceuticals, a distributor of pharmaceuticals and nutraceuticals, to extend the

Radius Health, a developer of new drug therapies for osteoporosis and women’s health, has dosed the first patient in the company’s proof-of-concept Phase IIa study of RAD1901, an

Corporate Update “We accomplished many significant Company goals during 2008 and especially in the fourth quarter, despite the current market conditions which have negatively impacted our share price,”

According to Regenerx, RGN-137 is a topical gel formulation of thymosin beta 4 peptide. The drug candidate was found to be safe and well-tolerated at all three dose

According to Celsis, ReACT assays use proprietary selections of ribosomal RNA sequences to confirm or to rule out the presence of Gram-negative organisms, Staphylococcus aureus, yeast and mold,

A total of 26 subjects completed either 12 or 24 weeks of treatment during Phase II studies – 23 of the 26 subjects continue to receive treatment in

The first phase of this collaboration grant will be a feasibility study using reagents developed by Foundation for Innovative New Diagnostics (FIND) to develop assays on the Ramp